ArticleMedicine2025
Plasma exchange combined with low-dose rituximab treatment: A case report of severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in the elderly.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
rationaleAntineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a form of necrotizing vasculitis not mediated by immune complexes, affecting multiple organs. The disease is particularly dangerous in its active stage, with high morbidity and mortality rates, especially among older patients. This study provides a possible treatment for ANCA in the elderly. PATIENT CONCERNS: An 84-year-old man developed an intermittent cough of unknown etiology in early February 2024, accompanied by hemoptysis, sore throat, dry mouth, arthralgia, fatigue, and occasional low fever. He had a history of chronic kidney disease for over 14 years and had been diagnosed with AAV and ANCA-associated nephritis for more than 9 months. DIAGNOSES: Laboratory tests in the rheumatology department revealed C-ANCA positivity, proteinase 3 > 200 RU/mL, and an ANCA + proteinase 3 antibody concentration of 2300 IU/L. Serum creatinine concentration had increased to 457 μmol/L↑. Other autoantibodies, including anti-extra nuclear antigen, were negative. Based on these findings and the patient's clinical symptoms, the diagnosis of ANCA-associated vasculitis was confirmed. Imaging revealed patchy and reticular opacities in both lungs, with a butterfly-wing distribution along the hila, accompanied by a small amount of bilateral pleural effusion. Scattered petechiae were observed on both upper limbs.
interventionsThe patient's condition was critical and rapidly progressing. He received successive treatments, including methylprednisolone sodium succinate + cyclophosphamide, plasma exchange, blood purification, and repeated small-dose courses of rituximab and belimumab. OUTCOMES: After 6 months of treatment, the patient achieved clinical, radiological, and serological remission. Hemoptysis stopped, renal function improved, immune status returned to normal, and there was no sign of ANCA recurrence. He was successfully discharged. LESSONS: Rituximab offers a promising therapeutic option for older patients with chronic kidney disease complicated by AAV. Multiple small-dose rituximab regimens may reduce drug-related side effects, significantly lower treatment costs, and provide an effective, economically viable approach for clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.